Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Journal of Hematology
Erschienen in: International Journal of Hematology 2/2017

30.11.2016 | Progress in Hematology

New agents in HSC mobilization

verfasst von: Mélanie J. Domingues, Susan K. Nilsson, Benjamin Cao

Erschienen in: International Journal of Hematology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Mobilized peripheral blood (PB) is the most common source of hematopoietic stem cells (HSC) for autologous transplantation. Granulocyte colony stimulating factor (G-CSF) is the most commonly used mobilization agent, yet despite its widespread use, a considerable number of patients still fail to mobilize. Recently, a greater understanding of the interactions that regulate HSC homeostasis in the bone marrow (BM) microenvironment has enabled the development of new molecules that mobilize HSC through specific inhibition, modulation or perturbation of these interactions. AMD3100 (plerixafor), a small molecule that selectively inhibits the chemokine receptor CXCR4 is approved for mobilization in combination with G-CSF in patients with Non-Hodgkin’s lymphoma and multiple myeloma. Nevertheless, identifying mobilization strategies that not only enhance HSC number, but are rapid and generate an optimal “mobilized product” for improved transplant outcomes remains an area of clinical importance. In recent times, new agents based on recombinant proteins, peptides and small molecules have been identified as potential candidates for therapeutic HSC mobilization. In this review, we describe the most recent developments in HSC mobilization agents and their potential impact in HSC transplantation.
Literatur
1.
Philip T, Guglielmi C, Hagenbeek A, Somers R, Vanderlelie H, Bron D, et al. Autologous bone-marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkins-Lymphoma. N Engl J Med. 1995;333:1540–5.PubMedCrossRef
2.
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91–7.PubMedCrossRef
3.
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.PubMedCrossRef
4.
Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.PubMedCrossRef
5.
Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transpl. 2016;51:778–85.CrossRef
6.
Bendall LJ, Bradstock KF. G-CSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev. 2014;25:355–67.PubMedCrossRef
7.
Piedmonte DM, Treuheit MJ. Formulation of Neulasta (R) (pegfilgrastim). Adv Drug Deliver Rev. 2008;60:50–8.CrossRef
8.
To LB, Levesque JP, Herbert KE, Winkler IG, Bendall LJ, Hiwase DK, et al. Mobilisation strategies for normal and malignant cells. Pathology. 2011;43:547–65.PubMedCrossRef
9.
Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transpl. 2009;43:181–95.CrossRef
10.
To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118:4530–40.PubMedCrossRef
11.
Gertz MA. Current status of stem cell mobilization. Brit J Haematol. 2010;150:647–62.CrossRef
12.
Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102:2728–30.PubMedCrossRef
13.
Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, et al. Rapid mobilization of CD34 + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22:1095–102.PubMedCrossRef
14.
Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201:1307–18.PubMedPubMedCentralCrossRef
15.
Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006;6:93–106.PubMedCrossRef
16.
Mendez-Ferrer S, Scadden DT, Sanchez-Aguilera A. Bone marrow stem cells: current and emerging concepts. Ann Ny Acad Sci. 2015;1335:32–44.PubMedCrossRef
17.
18.
Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997;185:111–20.PubMedPubMedCentralCrossRef
19.
Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood. 1998;91:100–10.PubMed
20.
De Clercq E. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini-Rev Med Chem. 2005;5:805–24.PubMedCrossRef
21.
Uy GL, Rettig MP, Cashen AF. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Th. 2008;8:1797–804.CrossRef
22.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–6.PubMed
23.
Pusic I, DiPersio JF. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol. 2010;17:319–26.PubMedCrossRef
24.
25.
DeMarco SJ, Henze H, Lederer A, Moehle K, Mukherjee R, Romagnoli B, et al. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorg Med Chem. 2006;14:8396–404.PubMedCrossRef
26.
Robinson JA, DeMarco S, Gombert F, Moehle K, Obrecht D. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov Today. 2008;13:944–51.PubMedCrossRef
27.
Schmitt S, Weinhold N, Dembowsky K, Neben K, Witzens-Harig M, Braun M, et al. First results of a phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HSC) in multiple myeloma (MM). Blood. 2010;116:359–60.
28.
Karpova D, Brauninger S, Wiercinska E, Kraemer A, Stock B, Graff J, et al. Potent Stem Cell Mobilization with the Novel CXCR4 Antagonist POL6326-Results of a Phase IIa Dose Escalation Study in Comparison to G-CSF. Blood. 2015;126:511.
29.
Huang YH, Liu YC, Yen CF, Chen HC, Chen SJ, King CHR, et al. Rapid mobilization of murine hematopoietic stem and progenitor cells with TG-0054, a novel CXCR4 antagonist. Blood. 2009;114:1374–5.CrossRef
30.
Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-Benzoyl-TN14003. Stem Cells. 2007;25:2158–66.PubMedCrossRef
31.
Chung DT, Chang LW, Huang YH, Tsai CY, Hsu CH, King CHR, et al. TG-0054, a novel and potent stem cell mobilizer, displays excellent PK/PD and safety profile in phase I trial. Blood. 2009;114:357.CrossRef
32.
Schuster MW, Hagog N, Jalilizeinali B, Funkhauser S, Yohannan MS, Sadler J, et al. Rapid mobilization Of CD34+ progenitor cells with TG0054-03, a novel CXC chemokine receptor 4 (CXCR4) antagonoist. Blood. 2013;122:905.
33.
Nagler A, Shimoni A, Avivi I, Rowe JM, Beider K, Hardan I, et al. BKT140 is a novel CXCR4 antagonist with stem cell mobilization and antimyeloma effects: an open-label first human trial in patients with multiple myeloma undergoing stem cell mobilization for autologous transplantation. Blood. 2010;116:2260.
34.
Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res. 2014;20:469–79.PubMedCrossRef
35.
Peng SB, Zhang XY, Paul D, Kays LM, Gough W, Stewart J, et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2015;14:480–90.PubMedCrossRef
36.
Galsky MD, Vogelzang NJ, Conkling P, Raddad E, Polzer J, Roberson S, et al. A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res. 2014;20:3581–8.PubMedCrossRef
37.
Cho BS, Zeng ZH, Mu H, Wang ZQ, Konoplev S, McQueen T, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015;126:222–32.PubMedPubMedCentralCrossRef
38.
Rettig MP, Ghobadi A, Holt M, Meier S, Ritchey J, Tahirovic Y, et al. ALT-1188: A new CXCR4 antagonist in development for mobilization Of HSPCs. Blood. 2013;122:891.
39.
40.
Vela M, Aris M, Llorente M, Garcia-Sanz J, Kremer L. Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol. 2015;6:12.PubMedPubMedCentralCrossRef
41.
Hoggatt J, Pelus LM. Mobilization of hematopoietic stem cells from the bone marrow niche to the blood compartment. Stem Cell Res Ther. 2011;2:1–13.CrossRef
42.
Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9:537–50.PubMedCrossRef
43.
Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer therapeutics. Drug Discov Today. 2015;20:147–55.PubMedCrossRef
44.
Scheller M, Schwoebel F, Vossmeyer D, Leutz A. Rapid and efficient mobilization of murine hematopoietic stem and progenitor cells with Nox-A12, a new Spiegelmers (R)-based CXCR4/SDF-1(CXCL12) antagonist. Blood. 2011;118:1290–2995.
45.
Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C, et al. Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin Pharmacol Ther. 2013;94:150–7.PubMedCrossRef
46.
Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Laurent G, et al. Final results from the phase IIa study of the anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in combination with bortezomib and dexamethasone in patients with multiple myeloma. Blood. 2014;124:2111.
47.
Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S. Nanobodies and their potential applications. Nanomedicine-Uk. 2013;8:1013–26.CrossRef
48.
Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol. 2009;198:157–74.PubMedPubMedCentralCrossRef
49.
Jahnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. P Natl Acad Sci USA. 2010;107:20565–70.CrossRef
50.
Griffiths K, Dolezal O, Cao B, Nilsson SK, See HB, Pfleger KDG, et al. i-Bodies, human single domain antibodies that antagonize chemokine receptor CXCR4. J Biol Chem. 2016;291:12641–57.PubMedCrossRef
51.
Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3:687–94.PubMedCrossRef
52.
Angelopoulou MK, Tsirkinidis P, Boutsikas G, Vassilakopoulos TP, Tsirigotis P. New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients. Biomed Res Int. 2014;2014:835138.PubMedPubMedCentralCrossRef
53.
Dar A, Schajnovitz A, Lapid K, Kalinkovich A, Itkin T, Ludin A, et al. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia. 2011;25:1286–96.PubMedPubMedCentralCrossRef
54.
Itkin T, Gur-Cohen S, Spencer JA, Schajnovitz A, Ramasamy SK, Kusumbe AP, et al. Distinct bone marrow blood vessels differentially regulate haematopoiesis. Nature. 2016;532:323–8.PubMedCrossRef
55.
Zirafi O, Kim K-A, Ständker L, Mohr Katharina B, Sauter D, Heigele A, et al. Discovery and characterization of an endogenous CXCR4 antagonist. Cell Rep. 2015;11:737–47.PubMedCrossRef
56.
Zirafi O, Hermann PC, Munch J. Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4. J Leukocyte Biol. 2016;99:863–8.PubMedCrossRef
57.
Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med. 2006;12:657–64.PubMedCrossRef
58.
Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 2003;111:187–96.PubMedPubMedCentralCrossRef
59.
60.
Kim MG, Han N, Lee EK, Kim T. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transpl. 2015;50:523–30.CrossRef
61.
Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood. 1999;93:2491–501.PubMed
62.
Stiff P, Gingrich R, Luger S, Wyres MR, Brown RA, LeMaistre CF, et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin’s disease or non-Hodgkin’s lymphoma. Bone Marrow Transpl. 2000;26:471–81.CrossRef
63.
Herbert KE, Prince HM, Ritchie DS, Seymour JF. The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution. Expert Opin Biol Th. 2010;10:113–25.CrossRef
64.
Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Pavlovic S, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood. 1999;93:2798–806.PubMed
65.
Linker C, Anderlini P, Herzig R, Christiansen N, Somlo G, Bensinger W, et al. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transpl. 2003;9:405–13.CrossRef
66.
Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98:10–23.PubMedCrossRef
67.
King AG, Horowitz D, Dillon SB, Levin R, Farese AM, MacVittie TJ, et al. Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRO beta. Blood. 2001;97:1534–42.PubMedCrossRef
68.
Fukuda S, Bian HM, King AG, Pelus LM. The chemokine GRO beta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood. 2007;110:860–9.PubMedPubMedCentralCrossRef
69.
Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425:841–6.PubMedCrossRef
70.
Adams GB, Martin RP, Alley IR, Chabner KT, Cohen KS, Calvi LM, et al. Therapeutic targeting of a stem cell niche. Nat Biotechnol. 2007;25:238–43.PubMedCrossRef
71.
Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transpl. 2007;13:838–43.CrossRef
72.
Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, et al. Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transpl. 2012;18:1851–8.CrossRef
73.
Yu EW, Kumbhani R, Siwila-Sackman E, DeLelys M, Preffer FI, Leder BZ, et al. Teriparatide (PTH1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women. J Bone Miner Res. 2014;29:1380–6.PubMedPubMedCentralCrossRef
74.
He S, Chu JH, Vasu S, Deng YC, Yuan SZ, Zhang JY, et al. FLT3L and Plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome. Biol Blood Marrow Transplant. 2014;20:309–13.PubMedCrossRef
75.
76.
Anandasabapathy N, Breton G, Hurley A, Caskey M, Trumpfheller C, Sarma P, et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transpl. 2015;50:924–30.CrossRef
77.
Levesque J-P, Winkler IG. Cell adhesion molecules in normal and malignant hematopoiesis: from bench to bedside. Curr Stem Cell Rep. 2016;2:356–67.CrossRef
78.
Oostendorp RAJ, Dormer P. VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells. Leuk Lymphoma. 1997;24:423–35.PubMedCrossRef
79.
Craddock CF, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood. 1997;90:4779–88.PubMed
80.
Jing D, Oelschlaegel U, Ordemann R, Holig K, Ehninger G, Reichmann H, et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transpl. 2010;45:1489–96.CrossRef
81.
Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34 + hematopoietic progenitor cells in humans. Blood. 2008;111:3893–5.PubMedCrossRef
82.
Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of Natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–80.PubMedCrossRef
83.
Ramirez P, Rettig MP, Uy GL, Deych E, Holt MS, Ritchey JK, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood. 2009;114:1340–3.PubMedPubMedCentralCrossRef
84.
Leone DR, Giza K, Gill A, Dolinski BM, Yang W, Perper S, et al. An assessment of the mechanistic differences between two integrin alpha(4)beta(1) inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther. 2003;305:1150–62.PubMedCrossRef
85.
Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 2012;26:34–53.PubMedCrossRef
86.
Grassinger J, Haylock DN, Storan MJ, Haines GO, Williams B, Whitty GA, et al. Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood. 2009;114:49–59.PubMedCrossRef
87.
Cao B, Zhang Z, Grassinger J, Williams B, Heazlewood CK, Churches QI, et al. Therapeutic targeting and rapid mobilization of endosteal HSC using a small molecule integrin antagonist. Nat Commun. 2016;7:11077CrossRef
88.
Cao B, Hutt OE, Zhang Z, Li SH, Heazlewood SY, Williams B, et al. Design, synthesis and binding properties of a fluorescent alpha(9)beta(1)/alpha(4)beta(1) integrin antagonist and its application as an in vivo probe for bone marrow haemopoietic stem cells. Org Biomol Chem. 2014;12:965–78.PubMedCrossRef
89.
Grassinger J, Haylock DN, Williams B, Olsen GH, Nilsson SK. Phenotypically identical hemopoietic stem cells isolated from different regions of bone marrow have different biologic potential. Blood. 2010;116:3185–96.PubMedCrossRef
90.
Hoggatt J, Speth JM, Pelus LM. Concise review: sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilization. Stem Cells. 2013;31:2599–606.PubMedPubMedCentralCrossRef
91.
Di Giacomo F, Lewandowski D, Cabannes E, Nancy-Portebois V, Petitou M, Fichelson S, et al. Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells. Haematologica. 2012;97:491–9.PubMedPubMedCentralCrossRef
92.
Meldal M, Tornoe CW. Cu-catalyzed azide-alkyne cycloaddition. Chem Rev. 2008;108:2952–3015.PubMedCrossRef
93.
94.
Seeberger PH, Werz DB. Automated synthesis of oligosaccharides as a basis for drug discovery. Nat Rev Drug Discov. 2005;4:751–63.PubMedCrossRef
95.
Kook S, Cho J, Lee SB, Lee BC. The nucleotide sugar UDP-glucose mobilizes long-term repopulating primitive hematopoietic cells. J Clin Invest. 2013;123:3420–35.PubMedPubMedCentralCrossRef
96.
Yeoh JS, Ausema A, Wierenga P, de Haan G, van Os R. Mobilized peripheral blood stem cells provide rapid reconstitution but impaired long-term engraftment in a mouse model. Bone Marrow Transpl. 2007;39:401–9.CrossRef
97.
Ko H, Fricks I, Ivanov AA, Harden TK, Jacobson KA. Structure-activity relationship of uridine 5′-diphosphoglucose analogues as agonists of the human P2Y(14) receptor. J Med Chem. 2007;50:2030–9.PubMedPubMedCentralCrossRef
98.
Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673–83.PubMedCrossRef
99.
Chigaev A, Sklar LA, Schrader R, Stephens N, Raissy H, Winter SS. The evaluation of thioridazine as a hematopoietic progenitor cell mobilizing agent in healthy human subjects. J Clin Pharmacol. 2015;55:512–6.PubMedPubMedCentralCrossRef
100.
Ghobadi A, Rettig MP, Cooper ML, Holt MS, Ritchey JK, Eissenberg L, et al. Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis. Blood. 2014;124:2752–4.PubMedPubMedCentralCrossRef
101.
Giglio G, Romito S, Carrozza F, Musacchio M, Antuzzi G, Gigli R, et al. Successful mobilization of peripheral blood stem cells with bortezomib plus high-dose cyclophosphamide plus G-CSF in a light chain myeloma patient after failure with Total Therapy 2. Int J Hematol. 2009;90:81–6.PubMedCrossRef
102.
Abhyankar S, Lubanski P, DeJarnette S, Merkel D, Bunch J, Daniels K, et al. A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant. J Clin Apher. 2016;6:559–63.CrossRef
103.
Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, et al. Differential stem- and progenitor-cell trafficking by prostaglandin E-2. Nature. 2013;495:365–9.PubMedPubMedCentralCrossRef
104.
Boitano AE, Wang JA, Romeo R, Bouchez LC, Parker AE, Sutton SE, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329:1345–8.PubMedPubMedCentralCrossRef
105.
Zhang J, Ren XL, Shi W, Wang SH, Chen HX, Zhang BW, et al. Small molecule Me6TREN mobilizes hematopoietic stem/progenitor cells by activating MMP-9 expression and disrupting SDF-1/CXCR4 axis. Blood. 2014;123:428–41.PubMedCrossRef
106.
Lee HM, Wysoczynski M, Liu R, Shin DM, Kucia M, Botto M, et al. Mobilization studies in complement-deficient mice reveal that optimal AMD3100 mobilization of hematopoietic stem cells depends on complement cascade activation by AMD3100-stimulated granulocytes. Leukemia. 2010;24:573–82.PubMedCrossRef
Metadaten
Titel
New agents in HSC mobilization
verfasst von
Mélanie J. Domingues
Susan K. Nilsson
Benjamin Cao
Publikationsdatum
30.11.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 2/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2156-2

Weitere Artikel der Ausgabe 2/2017

International Journal of Hematology 2/2017 Zur Ausgabe

Case Report

Successful management of perioperative hemostasis in a patient with Glanzmann thrombasthenia who underwent a right total mastectomy

Original Article

A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity

Progress in Hematology

Extracellular molecules in hematopoietic stem cell mobilisation

Original Article

Mitophagy is increased during erythroid differentiation in β-thalassemia

Original Article

A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece

Original Article

Wnt signaling inhibitor FH535 selectively inhibits cell proliferation and potentiates imatinib-induced apoptosis in myeloid leukemia cell lines

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise